Biosimilars Market Overview
The biosimilars market is rapidly gaining momentum as healthcare systems worldwide look for cost-effective alternatives to biologic therapies. Biosimilars are biologic medical products that are highly similar to already approved biologics, offering the same therapeutic benefits with no clinically meaningful differences in terms of safety, efficacy, and quality.
These products are instrumental in driving down treatment costs, enhancing accessibility to biologic therapies, and fostering competitive pricing in the pharmaceutical industry. With a growing global emphasis on affordable biologics and supportive regulatory environments, biosimilars are poised to reshape the future of drug development and patient care.
Market Size, CAGR, and Forecast (as per EMR Data)
According to Expert Market Research:
Global Biosimilars Market Size in 2023: USD 29.91 Billion
Forecasted CAGR (2024–2032): 22.9%
Expected Market Value by 2032: USD 190.79 Billion
This rapid growth reflects strong policy support, patent expirations of blockbuster biologics, and increased biosimilar approvals globally.
For more information about this report visit
Market Segmentation
The biosimilars market is segmented by product, application, and region to understand its scope and future opportunities better.
By Product Type
Monoclonal Antibodies
Recombinant Hormones
Immunomodulators
Insulin
Hematopoietic Agents
Others
Monoclonal antibodies dominate the market due to their widespread use in cancer treatment and chronic autoimmune conditions like rheumatoid arthritis and Crohn’s disease.
By Application
Oncology
Autoimmune Diseases
Diabetes
Blood Disorders
Growth Hormone Deficiency
Others
Oncology is the leading segment, supported by the high cost of original biologics and the growing prevalence of cancer globally.
By Region
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Europe leads the global biosimilars market, thanks to its early adoption, favorable regulations, and widespread public healthcare systems. However, Asia Pacific is expected to register the fastest growth due to increasing biosimilar production in countries like India, China, and South Korea.
Key Growth Drivers
Patent Expiry of Major Biologics
Many blockbuster biologics, including Humira®, Remicade®, and Herceptin®, have lost or are nearing patent expiration, opening the door for biosimilar versions.
Rising Healthcare Costs and Demand for Affordable Treatments
Biosimilars offer up to 30–40% cost savings over original biologics, significantly easing the financial burden on healthcare systems and patients.
Growing Prevalence of Chronic Diseases
Increasing incidences of cancer, diabetes, and autoimmune diseases have fueled the demand for biologic drugs, subsequently boosting biosimilar development.
Supportive Government Regulations and Approvals
Regulatory agencies like the FDA, EMA, and WHO have established clear pathways for biosimilar approvals, promoting faster launches and market access.
Expanding R&D and Technological Advances
Major pharmaceutical companies are investing in advanced biosimilar R&D to ensure product quality, safety, and scalability, driving market penetration.
Market Challenges
High Manufacturing Complexity
Unlike generics, biosimilars are complex to develop and require sophisticated infrastructure and long development cycles, increasing costs and risks.
Regulatory and Market Access Hurdles
Gaining regulatory approval and physician trust remains a challenge, especially in emerging markets with less-defined biosimilar guidelines.
Brand Loyalty and Prescriber Hesitation
Many clinicians remain cautious about switching stable patients from branded biologics to biosimilars, slowing down adoption in some regions.
Intellectual Property (IP) Litigation
Legal battles and patent extensions by originator companies often delay biosimilar entry into lucrative markets.
Top Companies (Key Players)
As per EMR, the leading companies in the global biosimilars market include:
Pfizer Inc.
Sandoz International GmbH (a Novartis division)
Amgen Inc.
Celltrion Healthcare Co., Ltd.
Biocon Biologics Limited
Samsung Bioepis Co., Ltd.
Mylan N.V. (part of Viatris Inc.)
Teva Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
These companies dominate the global biosimilar pipeline, production, and commercialization. They leverage strategic partnerships, strong R&D capabilities, and global distribution networks to stay competitive.
Recent Developments
Pfizer launched multiple biosimilars targeting oncology and inflammatory diseases and is focusing on market expansion in the U.S. and Europe.
Biocon Biologics and Viartis (Mylan) expanded their biosimilar portfolio and received FDA approvals for interchangeable insulin glargine.
Samsung Bioepis continues global expansion with new approvals in the EU and Asia Pacific for biosimilars targeting breast cancer and autoimmune disorders.
Amgen has expanded its oncology biosimilar portfolio and invested in real-world studies to support biosimilar switching confidence among clinicians.
FAQs for SEO (Answer-Focused for Featured Snippets)
What are biosimilars?
Biosimilars are biologic medicines that are highly similar to an already approved reference biologic, with no clinically significant differences in terms of safety, purity, or efficacy.
How big is the global biosimilars market?
As of 2023, the global biosimilars market was valued at USD 29.91 billion and is projected to reach USD 190.79 billion by 2032.
What is driving the growth of the biosimilars market?
Key drivers include patent expiries, rising healthcare costs, chronic disease burden, and supportive regulations enabling biosimilar approvals and market access.
Which are the top biosimilar companies?
Major players include Pfizer, Amgen, Sandoz, Celltrion, Biocon, and Samsung Bioepis.
Which region leads the biosimilars market?
Europe currently leads due to early adoption and well-established regulatory pathways, but Asia Pacific is growing rapidly.
The biosimilars market is set to revolutionize the global pharmaceutical landscape by making biologic therapies more accessible and affordable. With a projected market value of over USD 190 billion by 2032 and a CAGR of 22.9%, biosimilars represent one of the most promising growth sectors in modern medicine.
Find More Report:
CDMO Market trend
Surgical Site Infection (SSI) Drug Pipeline Analysis size
Transitional Cell Carcinoma Drug Pipeline Analysis share
